Chimerix

Management Team

Chimerix is led by a veteran team with deep experience and a successful track record in the discovery and development of novel therapeutics, and specifically, in medicines that treat viral and infectious diseases. Collectively, members of the team have participated in the filing of more than 40 Investigational New Drug (IND) applications and more than 20 New Drug Applications (NDA) with the U.S. Food and Drug Administration.

George Painter, Ph.D.

Chairman of the Board and Chief Scientific Officer

With over 31 years of experience and a track record of successful antiviral therapeutic development, George Painter, Chairman of the Board and Chief Scientific Officer, leads the Chimerix team in advancing a world-class antiviral pipeline.  Dr. Painter served as the President and CEO of Chimerix from 2002 until April 2010. Prior to joining Chimerix, he held the position of Executive Vice President, Research and Development, at Triangle Pharmaceuticals, where he was a member of the founding management team.  Previously, he served as Director of Research Process and International Deputy Therapeutic Head for Antiviral Research at Glaxo Wellcome Inc.  In addition, Dr. Painter held positions at Burroughs Wellcome Co., including Director of Chemistry and Director of Virology.  Dr. Painter is a co-inventor on over forty-five patents, six of which have led to approved commercially-available drugs or combinations of drugs for the treatment of HIV and hepatitis B.  He has led international teams which generated data for nine investigational new drug applications and three new drug applications.  Dr. Painter earned a B.S. in chemistry, an M.S. in physical organic chemistry and a Ph.D. in synthetic chemistry from Emory University.

Kenneth I. Moch

President and CEO

Kenneth Moch joined Chimerix in 2009 as Chief Operating Officer and was named President and Chief Executive Officer in April, 2010.  He brings more than 25 years of experience in managing and financing biomedical technologies, and having played a key role in building several life science companies. Prior to joining Chimerix, Mr. Moch founded Euclidean Life Science Advisors, a provider of strategic advisory services to life sciences companies, where he most recently served as President and CEO of BioMedical Enterprises, Inc. Previously, he was Managing Director, Healthcare Investment Banking, at ThinkEquity Partners. In 1995, Mr. Moch joined Alteon Inc., a biotechnology company specializing in small molecule therapeutics for cardiovascular aging and diabetic complications, where he served as President and CEO from 1998 to 2005. Mr. Moch served as President and CEO of Biocyte Corporation, the cellular therapy company that pioneered the collection and commercial application of cord blood stem cells. Prior, he was co-founder and Vice President of The Liposome Company, Inc. Earlier in his career, Mr. Moch was a management consultant with McKinsey & Company, Inc. Mr. Moch holds an A.B. in biochemistry from Princeton University and an MBA from the Stanford University Graduate School of Business.

Gwendolyn P. Painter, M.D., MPH

Chief Medical Officer

Wendy Painter was named Chief Medical Officer of Chimerix in 2009 and has been working with Chimerix since 2002 in a consulting capacity.  In this capacity, she has provided medical oversight and clinical consulting to the company’s development efforts.  Dr. Painter has 20 years of experience in the pharmaceutical industry, including work in clinical development, clinical safety and pharmacovigilance, occupational and environmental medicine.  Prior to her current role, she served as Medical Director at GlaxoSmithKline where she had responsibility for worldwide antiviral clinical safety, and was involved in a number of antiviral IND and NDA submissions.  Dr. Painter earned an M.S. in organic chemistry at Emory University and an M.D. degree at the University Of Miami School Of Medicine.  She later obtained an MPH in epidemiology at University of North Carolina, Chapel Hill, and completed a fellowship in occupational medicine at Duke University, where she maintains an academic appointment.

Merrick Almond, Ph.D.

Vice President, Chemistry

Merrick Almond joined Chimerix as Vice President, Chemistry, in 2002, bringing 16 years of experience in antiviral research and was promoted to Vice President of Research in 2008. Prior, Dr. Almond was Director, Chemistry at Triangle Pharmaceuticals, where he was responsible for establishing a process exploration and optimization group that invented novel processes for five compounds under development. In addition, he chaired Triangle’s Patent Committee with responsibility to review and recommend patentable inventions. Prior to Triangle, Dr. Almond spent nine years in research positions at Burroughs Wellcome, and held the position of Research Investigator at Glaxo Wellcome. During his time at Wellcome, he was a recipient of the Wellcome Synthetic Organic Achievement Prize. He has published 22 scientific papers and is inventor/co-inventor of several patents. Dr. Almond earned a B.S. in biochemistry from the College of Environmental Science and Forestry in Syracuse, NY, and a Ph.D. in medicinal chemistry from Purdue University. He completed his postdoctoral research at Duke University.

Pamela Goss

Controller and Chief Accounting Officer

Pamela Goss joined Chimerix as Controller and Chief Accounting Officer in April 2005.  Ms. Goss came to Chimerix from Gilead Sciences, Inc., where she was the Manager of Financial Planning and Analysis for the Durham, North Carolina site.  At Gilead, she managed all financial functions at the Durham site and played a critical role in the successful integration of Triangle Pharmaceuticals, Inc., and Gilead, after Triangle was acquired in 2003.  Previously, Ms. Goss was the Senior Associate Director of Finance for Triangle Pharmaceuticals, Inc., with responsibilities that included financial reporting for the publicly-traded biotechnology company, as well as strategic financial planning for mergers, acquisitions and alliances.  She was a key contributor to the strategic alliance between Triangle and Abbott Laboratories, serving as the finance liaison for the alliance.  Ms. Goss is a Certified Public Accountant and earned a B.S. with high honors from North Carolina State University.

Timothy King

Vice President, Clinical Operations

Timothy King joined Chimerix as Vice President, Clinical Operations, in 2010. Mr. King has over 20 years of global experience managing and directing device and drug development clinical trials. Most recently he served as a Group Director at Quintiles, where he had responsibility for more than 20 Phase I to IV trials in over 40 countries for a wide range of drugs, biologics, devices and diagnostics. This portfolio of studies was valued in excess of 300 Million USD. Mr. King’s prior experience includes serving as the Head of Clinical Operations for Infectious Diseases, Hepatology, Vaccines, and Transplants at Duke Clinical Research Institute where he oversaw programs in cytomegalovirus, hepatitis, and HIV, valued at 100 Million USD. Mr. King holds a masters degree in epidemiology from the University of North Carolina.

Hervé Momméja-Marin, M.D.

Vice President, Clinical Research

With over 20 years of global medical and clinical research experience in infectious and respiratory disease and clinical medicine, Dr. Momméja-Marin joined Chimerix as Vice President, Clinical Research in 2010. Most recently he was Senior Medical Director, Infectious Diseases, for i3 Research, a contract research organization, where he was the lead therapeutic expert in infectious diseases. His background includes numerous Phase I through Phase IV clinical trials, including more than 25 late-stage trials. Previously, Dr. Momméja-Marin was Director of Clinical Research for Gilead Sciences, Inc., where he was responsible for the global development of hepatitis B and hepatitis C programs. He also held the positions of Clinical Research Physician at Triangle Pharmaceuticals and Physician of Internal Medicine and Infectious Diseases at Assistance Publique- Hôpitaux de Paris in France. Dr. Momméja-Marin received a medical degree from Paris VII University, France. He is certified in internal medicine and multiple subspecialties.

Rosemary O'Mahony, Ph.D.

Vice President, Development

With over 21 years of experience in the development of pharmaceutical agents, Rosemary O'Mahony joined Chimerix in 2002 as Vice President, Development.  Most recently, Dr. O’Mahony held the position of Director, Chemical Development, at Triangle Pharmaceuticals until it was acquired by Gilead Sciences, Inc., in 2003.  As the Director of Chemical Development, Dr. O'Mahony was responsible for the large scale manufacture of bulk drug substance and was a key participant in the strategic alliance between Triangle and Abbott Laboratories.  She began her development career in the Chemical Development Group at Burroughs Wellcome and subsequently held several positions at Glaxo Wellcome, including Team Manager, Chemical Development, and Project Manager in the Worldwide Project Management Group. Dr. O'Mahony earned a B.S. in chemistry from Montclair State College and a Ph.D. in synthetic organic chemistry from the University of North Carolina at Chapel Hill.

Thomas A. Pitler, Ph.D.

Vice President, Business Development

Thomas Pitler joined Chimerix as Vice President, Business Development in April 2010. Prior to joining Chimerix, Dr. Pitler was Senior Vice President, Chief Business and Financial Officer at Neurogen, Inc., which was recently acquired by Ligand Pharmaceuticals.   He joined Neurogen in 1995 as a scientist in research and development.  In 1999, he became head of business development, subsequently moving into business and corporate development positions of increasing responsibility.  While at Neurogen, Dr. Pitler was responsible for the in-licensing of a Phase II clinical-stage compound from Wyeth, and led multi-million dollar out-licensing and technology deals with several international pharmaceutical companies.  Before joining Neurogen, Dr. Pitler was a Research Assistant Professor at the University of Maryland School of Medicine and held other academic positions.  He received a B.A. in Biology and a Ph.D. in Physiology from Wake Forest University.